Changing the Way Anti-Cancer Drugs Are Developed

Cell Therapeutics is a biopharmaceutical company focused on developing and commercializing novel cancer treatments.

We are focused on gaining approvals for our two phase III product candidates, pixantrone in relapsed or refractory aggressive non-Hodgkin's lymphoma, and OPAXIO in maintenance of ovarian cancer following complete remission after first-line treatment. We have one product in phase II clinical development, and other candidates in preclinical research. These products may address the therapeutic limitations of conventional cancer therapies.